Evidence map›Paper›PMID 41040511›Full record

ArticleFrontiers in oncology2025

Anti-lipolysis-stimulated lipoprotein receptor antibody-drug conjugate to treat triple-negative breast cancer.

Zhuoxin Zora Zhou, Davis Ballard, Tanvi Varadkar, Jiashuai Zhang, Zhantao Du, Ashley George, Aaron Krabacher, Rachel Yengo, Lufang Zhou, Xiaoguang Margaret Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhuoxin Zora Zhou *Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, United States.
Davis Ballard *Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, United States.
Tanvi VaradkarDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, United States.
Jiashuai ZhangDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, United States.
Zhantao DuDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, United States.
Ashley GeorgeDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, United States.
Aaron KrabacherDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, United States.
Rachel YengoDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, United States.
Lufang ZhouDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, United States.
Xiaoguang Margaret LiuDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, United States.

Funding

Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American WomenR01CA242917 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIU, RUNHUA RUNA, LIU, XIAOGUANG MARGARET · 2020 to 2024
$1.7M
NCI NIH HHS R01 CA242917
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype (ER

Indexed as

antibody-drug conjugate (ADC)evaluationslipolysis-stimulated lipoprotein receptor (LSR)targeted therapytriple-negative breast cancer (TNBC)

Identifiers

PMID41040511
PMCPMC12483854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.